The Centers for Disease Control and Prevention is not expected to change recommendations for hepatitis B vaccines in newborns, after its panel of advisers tabled Friday a much-awaited vote on the issue. The panel had been expected to recommend delaying the use of the vaccine in babies, currently administered shortly after birth, but some members expressed frustration over a lack of evidence about side effects and said more discussion was needed. One member also said the voting language wasn’t clear and could lead to confusing guidance.

See Full Page